ACADIA PHARMACEUTICALS INC. Shareholders' Equity
ACADIA PHARMACEUTICALS INC. (ACAD) had Shareholders' Equity of $1.31 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.31B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.25B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.23B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $917.27M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.31B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.25B 10-Q · filed 2026-08-05 |
| 2025-12-31 | $1.23B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $917.27M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $822.38M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $765.24M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $732.79M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $577.18M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $516.70M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $464.04M 10-Q · filed 2025-08-07 |
| 2023-12-31 | $431.75M 10-K · filed 2026-02-26 |
| 2023-09-30 | $362.17M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $395.79M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $374.26M 10-Q · filed 2024-08-07 |
| 2022-12-31 | $400.41M 10-K · filed 2026-02-26 |
| 2022-09-30 | $425.69M 10-Q · filed 2023-11-03 |
| 2022-06-30 | $434.85M 10-Q · filed 2023-11-03 |
| 2022-03-31 | $444.80M 10-Q · filed 2023-08-03 |
| 2021-12-31 | $540.89M 10-K · filed 2025-02-27 |
| 2021-09-30 | $566.96M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $564.84M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $581.61M 10-Q · filed 2022-08-09 |
| 2020-12-31 | $627.01M 10-K · filed 2024-02-28 |
| 2020-09-30 | $654.87M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $663.01M 10-Q · filed 2021-11-09 |
| 2020-03-31 | $638.38M 10-Q · filed 2021-08-05 |
| 2019-12-31 | $699.13M 10-K · filed 2023-02-28 |
| 2019-09-30 | $689.29M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $388.91M 10-Q · filed 2020-11-04 |
| 2019-03-31 | $418.36M 10-Q · filed 2020-08-06 |
| 2018-12-31 | $479.08M 10-K · filed 2022-03-01 |
| 2018-09-30 | $223.44M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $264.72M 10-Q · filed 2019-10-31 |
| 2018-03-31 | $304.17M 10-Q · filed 2019-08-01 |
| 2017-12-31 | $335.29M 10-K · filed 2021-02-25 |
| 2017-09-30 | $377.33M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $415.14M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $457.52M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $518.41M 10-K · filed 2020-02-27 |
| 2016-09-30 | $578.06M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $408.81M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $445.25M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $199.76M 10-K · filed 2019-02-27 |
| 2015-09-30 | $227.35M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $255.82M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $285.09M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $309.49M 10-K · filed 2018-02-27 |
| 2014-09-30 | $330.49M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $350.11M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $365.46M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $182.13M 10-K · filed 2017-02-28 |
| 2013-09-30 | $180.75M 10-Q · filed 2013-11-06 |
| 2013-06-30 | $181.47M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $79.66M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $84.98M 10-K · filed 2016-02-29 |
| 2012-09-30 | $17.66M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $12.71M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $17.59M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $23.36M 10-K · filed 2015-02-26 |
| 2011-09-30 | $28.14M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $32.82M 10-Q · filed 2011-08-10 |
| 2010-12-31 | $29.69M 10-K · filed 2014-02-27 |
| 2009-12-31 | $12.11M 10-K · filed 2013-03-12 |
| 2008-12-31 | $52.99M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |